肺癌靶向基因的研究及价值  

Advancement and the value of targeted gene related to lung cancer

作　　者：郭雨平[1] 汪得喜[1] 

机构地区：[1]暨南大学医学院第四附属医院广州市红十字会医院呼吸科,510220

出　　处：《国际肿瘤学杂志》2013年第7期512-515,共4页Journal of International Oncology

基　　金：广东省医学科研项目（2012A2012502）;广州市卫生局医药卫生科研项目（20121A011049）.

摘　　要：肺癌的发生发展与众多肺癌相关基因的表达及突变有密切关系。近期国内外肺癌的相关基因研究显示，COPS3基因的表达在刺激肺癌细胞增殖的过程中可能发挥关键作用，棘皮动物微管样蛋白4-间变淋巴瘤激酶融合基因与表皮生长因子受体突变共存，GA733基因与肺癌的生存期密切相关。同时成纤维细胞生长因子受体1、高迁移率蛋白家族、类清道夫受体成员5和表皮生长因子受体为肺癌的基因靶向治疗提供了新思路。肺癌的治疗需要多基因联合治疗和基因治疗联合常规治疗。The occurrence and development of lung cancer are closely related to gene expression and mutations. Recent studies of lung cancer related genes show that the expression of COPS3 gene may play a key role in the lung cancer cell proliferation. Echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase fusion gene and epidermal growth factor receptor mutations coexist. GA733 gene is closely related to lung cancer survival. Fibroblast growth factor receptor 1, high mobility protein family, members of the scavenger receptor class 5 and epidermal growth factor receptor provide new ideas for targeted therapy of lung cancer. For the therapy of lung cancer, multiple gene therapy and gene therapy combined with conventional treatment is required.

关 键 词：肺肿瘤 基因表达 基因疗法 

分 类 号：R734.2[医药卫生—肿瘤]